Metropolis Healthcare Limited has announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. For the quarter ended March 31, 2026, the company reported a standalone revenue of Rs. 35,203.12 Lakhs, reflecting a 5.17% increase from the previous quarter’s Rs. 33,471.38 Lakhs and a 12.94% growth compared to Rs. 31,168.61 Lakhs in the corresponding quarter of the previous year. Net profit for the current quarter stood at Rs. 3,506.44 Lakhs, marking a 9.47% increase from Rs. 3,203.04 Lakhs in the previous quarter and a 16.27% rise from Rs. 3,015.68 Lakhs in the same period last year. The Board has also declared a second interim dividend of INR 1/- per equity share for the financial year 2025-26.

Metropolis Healthcare Limited is a leading diagnostic company in India, founded in 1981 and headquartered in Mumbai. The company offers a comprehensive range of clinical laboratory tests and profiles used for disease prediction, screening, and monitoring, alongside support services for clinical research organizations. As the second-largest pathology laboratory chain in India, Metropolis has significantly expanded its footprint in 2025 through strategic acquisitions, including Ambika Pathology Laboratory in Kolhapur, Scientific Pathology in Agra, and Dehradun-based diagnostic firms. Led by Executive Chairperson Ameera Shah, the firm recently launched a Centre of Genomics in partnership with Illumina to scale advanced precision diagnostics across its extensive network.